Orphan Drugs Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Increase in Prevalence of Rare Diseases and Favorable Government Policies
   3. Market Restraints
      1. Limited Patient Pool and Commercial Viability
      2. High Development Costs and Resource Intensiveness
   4. Market Opportunities
      1. Expanding Scope of Gene Therapies for Rare Diseases
   5. Market Trends
      1. Precision Medicine and Targeted Therapies
      2. Rising Interest in Repurposing Existing Drugs
5. MARKET SEGMENTATION
   1. By Therapy Type
      1. Oncology
      2. Hematology
      3. Neurology
      4. Endocrinology
      5. Cardiovascular
      6. Respiratory
      7. Immunotherapy
      8. Infectious Diseases
      9. Others
   2. By Drug Type
      1. Biologics
      2. Non-biologics
   3. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
      4. Others
   4. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
   15. Alexion Pharmaceuticals, Inc.
   15. Amgen Inc.
   15. Bristol-Myers Squibb Company
   15. Biogen
   15. Celldex Therapeutics
   15. Eli Lilly and Company
   15. Eisai Co., Ltd.
   15. F. Hoffmann-La Roche Ltd.
   15. GSK plc.
   15. Kyowa Kirin Co., Ltd.
   15. Merck KGaA
   15. Novo Nordisk A/S
   15. Novartis AG
   16. Pfizer Inc.
   15. Takeda Pharmaceutical Company Limited
7. Vertex Pharmaceuticals Incorporated MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global orphan drugsmarket?

The global market of orphan drugsis projected to reach USD 4.7Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global orphan drugsmarket?

The global orphan drugsmarket has an estimated annual growth rate of 10.4% .

Q.3. What are the recent trends of orphan drugsmarket?

Precision medicine and targeted therapies and rising interest in repurposing existing drugsare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in orphan drugs?

The major companies profiled in this report include Alexion Pharmaceuticals, Inc., Amgen Inc., Bristol-Myers Squibb Company, Biogen, Celldex Therapeutics, Eli Lilly and Company, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., GSK plc., Kyowa Kirin Co., Ltd., Merck KGaA, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited., among others.                                   

Q.5. Which region is estimated to held highest CAGR inorphan drugsmarket?

North America is estimated to hold biggest share in the market for orphan drugs.